Exagen Profit Margin

The latest profit margin for XGN is -29.49% as of March 2026. That compares with -27.34% in the prior-year period — down 7.9% year over year. That is below the Healthcare sector average of 15.29%. Investors often review this figure alongside Exagen's historical trend and sector peers before judging valuation or financial health.

Over the past year, XGN's profit margin moved from -27.34% to -29.49% — a 7.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Exagen's valuation or profitability profile.

Against Healthcare companies, XGN currently prints -29.49% for profit margin, while the sector average sits near 15.29%. That is roughly 292.8% below the sector mean. Large gaps often invite a closer look at Exagen's growth, margins, and balance sheet.

Profit Margin shows how effectively Exagen converts resources into returns. At -29.49%, XGN may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -27.34% in the prior-year period — down 7.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting XGN's profit margin (-29.49%), review year-over-year change from -27.34%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.